Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
Subscribe

Logo for

Science 323 (5921): 1610-1614

Copyright © 2009 by the American Association for the Advancement of Science

Variants of the Antibody Herceptin That Interact with HER2 and VEGF at the Antigen Binding Site

Jenny Bostrom,1,2 Shang-Fan Yu,3 David Kan,3 Brent A. Appleton,1 Chingwei V. Lee,1,2 Karen Billeci,4 Wenyan Man,1 Franklin Peale,5 Sarajane Ross,3 Christian Wiesmann,1 Germaine Fuh1,2*

Abstract: The interface between antibody and antigen is often depicted as a lock and key, suggesting that an antibody surface can accommodate only one antigen. Here, we describe an antibody with an antigen binding site that binds two distinct proteins with high affinity. We isolated a variant of Herceptin, a therapeutic monoclonal antibody that binds the human epidermal growth factor receptor 2 (HER2), on the basis of its ability to simultaneously interact with vascular endothelial growth factor (VEGF). Crystallographic and mutagenesis studies revealed that distinct amino acids of this antibody, called bH1, engage HER2 and VEGF energetically, but there is extensive overlap between the antibody surface areas contacting the two antigens. An affinity-improved version of bH1 inhibits both HER2- and VEGF-mediated cell proliferation in vitro and tumor progression in mouse models. Such "two-in-one" antibodies challenge the monoclonal antibody paradigm of one binding site, one antigen. They could also provide new opportunities for antibody-based therapy.

1 Department of Protein Engineering, Genentech, 1 DNA Way, South San Francisco, CA 94080, USA.
2 Department of Antibody Engineering, Genentech, 1 DNA Way, South San Francisco, CA 94080, USA.
3 Department of Translational Oncology, Genentech, 1 DNA Way, South San Francisco, CA 94080, USA.
4 Department of Assay and Automation Technology, Genentech, 1 DNA Way, South San Francisco, CA 94080, USA.
5 Department of Pathology, Genentech, 1 DNA Way, South San Francisco, CA 94080, USA.

* To whom correspondence should be addressed. E-mail: gml{at}gene.com

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Antibody Conjugation Approach Enhances Breadth and Potency of Neutralization of Anti-HIV-1 Antibodies and CD4-IgG.
J. Gavrilyuk, H. Ban, H. Uehara, S. J. Sirk, K. Saye-Francisco, A. Cuevas, E. Zablowsky, A. Oza, M. S. Seaman, D. R. Burton, et al. (2013)
J. Virol. 87, 4985-4993
   Abstract »    Full Text »    PDF »
Pyroglutamate and O-Linked Glycan Determine Functional Production of Anti-IL17A and Anti-IL22 Peptide-Antibody Bispecific Genetic Fusions.
X. Zhong, E. Kieras, E. Sousa, A. D'Antona, J. C. Baber, T. He, J. Desharnais, L. Wood, D. Luxenberg, M. Stahl, et al. (2013)
J. Biol. Chem. 288, 1409-1419
   Abstract »    Full Text »    PDF »
The Intriguing Options of Multispecific Antibody Formats for Treatment of Cancer.
U. H. WEIDLE, G. TIEFENTHALER, E. H. WEISS, G. GEORGES, and U. BRINKMANN (2013)
Cancer Genomics Proteomics 10, 1-18
   Abstract »    Full Text »    PDF »
Heterobivalent ligands target cell-surface receptor combinations in vivo.
L. Xu, J. S. Josan, J. Vagner, M. R. Caplan, V. J. Hruby, E. A. Mash, R. M. Lynch, D. L. Morse, and R. J. Gillies (2012)
PNAS 109, 21295-21300
   Abstract »    Full Text »    PDF »
LUZ-Y, a Novel Platform for the Mammalian Cell Production of Full-length IgG-bispecific Antibodies.
B. J. Wranik, E. L. Christensen, G. Schaefer, J. K. Jackman, A. C. Vendel, and D. Eaton (2012)
J. Biol. Chem. 287, 43331-43339
   Abstract »    Full Text »    PDF »
Computer-aided antibody design.
D. Kuroda, H. Shirai, M. P. Jacobson, and H. Nakamura (2012)
Protein Eng. Des. Sel. 25, 507-522
   Abstract »    Full Text »    PDF »
General strategy for the generation of human antibody variable domains with increased aggregation resistance.
K. Dudgeon, R. Rouet, I. Kokmeijer, P. Schofield, J. Stolp, D. Langley, D. Stock, and D. Christ (2012)
PNAS 109, 10879-10884
   Abstract »    Full Text »    PDF »
Effects of Anti-VEGF on Pharmacokinetics, Biodistribution, and Tumor Penetration of Trastuzumab in a Preclinical Breast Cancer Model.
C. V. Pastuskovas, E. E. Mundo, S. P. Williams, T. K. Nayak, J. Ho, S. Ulufatu, S. Clark, S. Ross, E. Cheng, K. Parsons-Reponte, et al. (2012)
Mol. Cancer Ther. 11, 752-762
   Abstract »    Full Text »    PDF »
Dual Specificity of Anti-CXCL10-CXCL9 Antibodies Is Governed by Structural Mimicry.
S. Fagete, F. Rousseau, G. Magistrelli, F. Gueneau, U. Ravn, M. H. Kosco-Vilbois, and N. Fischer (2012)
J. Biol. Chem. 287, 1458-1467
   Abstract »    Full Text »    PDF »
Converging on an HIV Vaccine.
B. Korber and S. Gnanakaran (2011)
Science 333, 1589-1590
   Abstract »    Full Text »    PDF »
Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies.
W. Schaefer, J. T. Regula, M. Bahner, J. Schanzer, R. Croasdale, H. Durr, C. Gassner, G. Georges, H. Kettenberger, S. Imhof-Jung, et al. (2011)
PNAS 108, 11187-11192
   Abstract »    Full Text »    PDF »
Cross-domain inhibition of TACE ectodomain.
C. J. Tape, S. H. Willems, S. L. Dombernowsky, P. L. Stanley, M. Fogarasi, W. Ouwehand, J. McCafferty, and G. Murphy (2011)
PNAS 108, 5578-5583
   Abstract »    Full Text »    PDF »
Involvement of functional autoantibodies against vascular receptors in systemic sclerosis.
G. Riemekasten, A. Philippe, M. Nather, T. Slowinski, D. N. Muller, H. Heidecke, M. Matucci-Cerinic, L. Czirjak, I. Lukitsch, M. Becker, et al. (2011)
Ann Rheum Dis 70, 530-536
   Abstract »    Full Text »    PDF »
Stable IgG-like Bispecific Antibodies Directed toward the Type I Insulin-like Growth Factor Receptor Demonstrate Enhanced Ligand Blockade and Anti-tumor Activity.
J. Dong, A. Sereno, W. B. Snyder, B. R. Miller, S. Tamraz, A. Doern, M. Favis, X. Wu, H. Tran, E. Langley, et al. (2011)
J. Biol. Chem. 286, 4703-4717
   Abstract »    Full Text »    PDF »
Chemical generation of bispecific antibodies.
V. R. Doppalapudi, J. Huang, D. Liu, P. Jin, B. Liu, L. Li, J. Desharnais, C. Hagen, N. J. Levin, M. J. Shields, et al. (2010)
PNAS 107, 22611-22616
   Abstract »    Full Text »    PDF »
Structural basis for high-affinity HER2 receptor binding by an engineered protein.
C. Eigenbrot, M. Ultsch, A. Dubnovitsky, L. Abrahmsen, and T. Hard (2010)
PNAS 107, 15039-15044
   Abstract »    Full Text »    PDF »
Development of a Two-part Strategy to Identify a Therapeutic Human Bispecific Antibody That Inhibits IgE Receptor Signaling.
J. Jackman, Y. Chen, A. Huang, B. Moffat, J. M. Scheer, S. R. Leong, W. P. Lee, J. Zhang, N. Sharma, Y. Lu, et al. (2010)
J. Biol. Chem. 285, 20850-20859
   Abstract »    Full Text »    PDF »
SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies.
J. H. Davis, C. Aperlo, Y. Li, E. Kurosawa, Y. Lan, K.-M. Lo, and J. S. Huston (2010)
Protein Eng. Des. Sel. 23, 195-202
   Abstract »    Full Text »    PDF »
Whither HER2-Related Therapeutics?.
P. De and B. Leyland-Jones (2010)
J. Clin. Oncol. 28, 1091-1096
   Full Text »    PDF »
Engineered Proteins Pull Double Duty.
J. R. Cochran (2010)
Science Translational Medicine 2, 17ps5
   Full Text »    PDF »
IMMUNOLOGY: Two-in-One Designer Antibodies.
P. W. H. I. Parren and D. R. Burton (2009)
Science 323, 1567-1568
   Abstract »    Full Text »    PDF »

To Advertise     Find Products

Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882